Interestingly, a strong correlation was observed between the expression levels of SREBP1c and YME1L1 and the severity of AKI in both control and AKI patients, suggesting the SREBP1c/YME1L1 signaling as a promising biomarker for AKI. Here, SREBF1 is linked to acute kidney injury.